JP2024534892A5 - - Google Patents

Info

Publication number
JP2024534892A5
JP2024534892A5 JP2024513940A JP2024513940A JP2024534892A5 JP 2024534892 A5 JP2024534892 A5 JP 2024534892A5 JP 2024513940 A JP2024513940 A JP 2024513940A JP 2024513940 A JP2024513940 A JP 2024513940A JP 2024534892 A5 JP2024534892 A5 JP 2024534892A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence described
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513940A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534892A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/042451 external-priority patent/WO2023034566A1/en
Publication of JP2024534892A publication Critical patent/JP2024534892A/ja
Publication of JP2024534892A5 publication Critical patent/JP2024534892A5/ja
Pending legal-status Critical Current

Links

JP2024513940A 2021-09-02 2022-09-02 抗dll3抗体及びその使用 Pending JP2024534892A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163240216P 2021-09-02 2021-09-02
US63/240,216 2021-09-02
PCT/US2022/042451 WO2023034566A1 (en) 2021-09-02 2022-09-02 Anti-dll3 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024534892A JP2024534892A (ja) 2024-09-26
JP2024534892A5 true JP2024534892A5 (cg-RX-API-DMAC7.html) 2025-09-10

Family

ID=85412872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513940A Pending JP2024534892A (ja) 2021-09-02 2022-09-02 抗dll3抗体及びその使用

Country Status (7)

Country Link
US (1) US20240368269A1 (cg-RX-API-DMAC7.html)
EP (1) EP4396224A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534892A (cg-RX-API-DMAC7.html)
CN (1) CN118159558A (cg-RX-API-DMAC7.html)
AU (1) AU2022337142A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230628A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023034566A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202421189A (zh) * 2022-08-22 2024-06-01 美商雅博得樂醫療公司 用於標靶性放射性同位素療法之多價免疫結合物
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途
WO2025061132A1 (en) * 2023-09-21 2025-03-27 Concept To Medicine Biotech Co., Ltd. Anti-dll3 antibodies and uses thereof
TW202600599A (zh) * 2024-03-11 2026-01-01 大陸商樂普生物科技股份有限公司 抗dll3抗體及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2530091T3 (pl) * 2010-01-29 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Przeciwciało przeciwko dll3
EP2598532B1 (en) * 2010-07-30 2017-07-12 Gianluca Moroncini Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof
ES2886123T3 (es) * 2012-01-31 2021-12-16 Regeneron Pharma Anticuerpos anti-asic1 y usos de los mismos
CN107922487A (zh) * 2015-03-06 2018-04-17 索伦托治疗有限公司 结合jag1的抗体治疗剂
EP3337517A4 (en) * 2015-08-20 2019-04-17 Abbvie Stemcentrx LLC ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
WO2019079762A1 (en) * 2017-10-20 2019-04-25 Children's National Medical Center METHODS OF DISCOVERING ANTIBODIES USING TRANSCRIPTOMES AND COMPOSITIONS DERIVED THEREFROM
US20220025037A1 (en) * 2018-04-03 2022-01-27 Dragonfly Therapeutics, Inc. Antibody variable domains targeting dll3, and use thereof
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
AU2019414968A1 (en) * 2018-12-27 2021-08-12 Gigagen, Inc. Anti-PD-1 binding proteins and methods of use thereof
US12441789B2 (en) * 2019-07-11 2025-10-14 Memorial Sloan Kettering Cancer Center DLL3-targeting antibodies and uses thereof
EP4065601A1 (en) * 2019-11-25 2022-10-05 Mabloc, LLC Anti-yellow fever virus antibodies, and methods of their generation and use

Similar Documents

Publication Publication Date Title
Tang et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments
JP5110768B2 (ja) モノクローナル抗体pam4ならびに膵臓癌の診断および治療のためのその使用
US20200255537A1 (en) Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
JP5139626B2 (ja) モノクローナル抗体hPAM4
US7183388B2 (en) Anti-MUC-1 single chain antibodies for tumor targeting
AU2016294858B2 (en) Radiolabelled antibody fragments for use in treating cancer
Spiegelberg et al. CD44v6‐Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody‐Based Approaches
WO2023034566A1 (en) Anti-dll3 antibodies and uses thereof
CN119499408A (zh) 靶向gpc3的分子探针以及用途
US11396538B2 (en) Antibodies to centrin-1, methods of making, and uses thereof
WO2025112030A1 (zh) B7h3结合多肽及其用途
US20240261446A1 (en) Anti-cd38 single domain antibodies in disease monitoring and treatment
WO2021229104A1 (en) Anti-cd38 single-domain antibodies in disease monitoring and treatment
JP5990523B2 (ja) 抗ヒトトランスフェリン受容体抗体を含む画像用腫瘍診断剤
US20230190968A1 (en) Anti-cd38 single-domain antibodies in disease monitoring and treatment
JP2024533162A5 (cg-RX-API-DMAC7.html)
Shah Pretargeted Cancer Radioimmunotherapy and Radioimaging Using Antibodies and Antibody Fragments
WO2024244006A1 (zh) 靶向itga2的抗体、其抗体药物缀合物以及用途
Li et al. Anti-MET immunoPET for non-small cell lung cancer using novel fully
Strand et al. Joanna Strand 1,*, Kjell Sjöström 2, Urpo J. Lamminmaki 3, Oskar Vilhelmsson Timmermand 1
Tang Against HER2/neu or Tumor-Associated Glycoprotein-72
Dijkers Development of new radiopharmaceutical for molecular imaging in oncology
IL165752A (en) Chimeric monoclonal antibody pam4, a conjugate comprising it and an antibody comprising the same or fragments thereof